Join to View Full Profile
200 1st St SWRochester, MN 55905
Phone+1 507-284-2511
Dr. Roeker is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2014 - 2017
Mayo Clinic College of MedicineClass of 2014
Certifications & Licensure
FL State Medical License 2021 - Present
MN State Medical License 2024 - 2027
NY State Medical License 2017 - 2026
NJ State Medical License 2020 - 2025
NH State Medical License 2024 - 2024
NC State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocy...Matthew S Davids, Toby A Eyre, Jennifer A Woyach, Lindsey E Roeker, Alessandra Ferrajoli
Lancet. 2026-07-09 - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guide...Sameer A Parikh, Paul J Hampel, Lindsey E Roeker, Yucai Wang, Mazie Tsang
Mayo Clinic Proceedings. 2026-07-01 - Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.Jacob D Soumerai, Meghan C Thompson, Ahmet Dogan, Venkatraman E Seshan, Kelsey Flaherty
Blood Advances. 2026-06-30
Abstracts/Posters
- Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center StudyLindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Chronic Lymphocytic Leukemia — an Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual MeetingMay 25th, 2025- Chronic Lymphocytic Leukemia — an Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)May 24th, 2025
- Pirtobrutinib’s Star Turn in Relapsed/Refractory CLL May Get an EncoreMarch 28th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
